Treatment of Intravenous Leiomyomatosis with Cardiac Extension following Incomplete Resection

Aim. Intravenous leiomyomatosis (IVL) with cardiac extension (CE) is a rare variant of benign uterine leiomyoma. Incomplete resection has a recurrence rate of over 30%. Different hormonal treatments have been described following incomplete resection; however no standard therapy currently exists. We review the literature for medical treatments options following incomplete resection of IVL with CE. Methods. Electronic databases were searched for all studies reporting IVL with CE. These studies were then searched for reports of patients with inoperable or incomplete resection and any further medical treatments. Our database was searched for patients with medical therapy following incomplete resection of IVL with CE and their results were included. Results. All studies were either case reports or case series. Five literature reviews confirm that surgery is the only treatment to achieve cure. The uses of progesterone, estrogen modulation, gonadotropin-releasing hormone antagonism, and aromatase inhibition have been described following incomplete resection. Currently no studies have reviewed the outcomes of these treatments. Conclusions. Complete surgical resection is the only means of cure for IVL with CE, while multiple hormonal therapies have been used with varying results following incomplete resection. Aromatase inhibitors are the only reported treatment to prevent tumor progression or recurrence in patients with incompletely resected IVL with CE.

[1]  A. Biri,et al.  Intravenous leiomyomatosis treated with aromatase inhibitor therapy , 2008, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[2]  W. Catherino,et al.  Uterine fibroids , 2016, Nature Reviews Disease Primers.

[3]  Xiao Chen,et al.  Selective estrogen receptor modulators (SERMs) for uterine leiomyomas. , 2012, The Cochrane database of systematic reviews.

[4]  S. Terraz,et al.  Intravenous leiomyomatosis of the uterus: link with new fertilisation methods? , 2009, Swiss medical weekly.

[5]  C. Nappi,et al.  Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas. , 2004, Human Reproduction.

[6]  P. Lumbiganon,et al.  Protective effect of depot‐medroxyprogesterone acetate on surgically treated uterine leiomyomas: a multicentre case‐control study , 1996, British journal of obstetrics and gynaecology.

[7]  M. Rinaldi,et al.  A one-stage approach to the treatment of intravenous leiomyomatosis extending to the right heart. , 2010, Journal of vascular surgery.

[8]  E. H. Schmidt,et al.  A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. , 2010, Fertility and sterility.

[9]  M. Mazur,et al.  Metastasizing leiomyoma of the uterus S‐phase fraction, estrogen receptor, and ultrastructure , 1980, Cancer.

[10]  P. Dartevelle,et al.  Late intracaval and intracardiac leiomyomatosis following hysterectomy for benign myomas treated by surgery and GnRH agonist. , 2001, Gynecologic oncology.

[11]  A. Al-Hendy,et al.  Innovative Oral Treatments of Uterine Leiomyoma , 2012, Obstetrics and gynecology international.

[12]  A. Lethaby,et al.  Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. , 2000, The Cochrane database of systematic reviews.

[13]  Qingle Li,et al.  [Surgical strategies on intravenous leiomyomatosis invading heart]. , 2011, Zhonghua yi xue za zhi.

[14]  N. Takai,et al.  A case of benign metastasizing leiomyoma treated by surgical castration followed by an aromatase inhibitor, anastrozole , 2009, Archives of Gynecology and Obstetrics.

[15]  G. Kilic,et al.  Treatment of symptomatic uterine leiomyoma with letrozole. , 2008, Reproductive biomedicine online.

[16]  J. F. Marshall,et al.  Intravenous Leiomyomatosis of the Uterus and Pelvis: Case Report , 1959, Annals of surgery.

[17]  P. Faries,et al.  Resection of an intravenous leiomyoma with intracardiac extension with use of endovascular techniques. , 2004, Journal of vascular surgery.

[18]  Huan Song,et al.  Aromatase inhibitors for uterine fibroids. , 2013, The Cochrane database of systematic reviews.

[19]  M. Diamond,et al.  Clinical update of smooth muscle tumors of the uterus. , 2005, Journal of minimally invasive gynecology.

[20]  J. Grenier,et al.  Effect of Decapeptyl, an agonistic analog of gonadotropin-releasing hormone on estrogens, estrogen sulfates, and progesterone receptors in leiomyoma and myometrium. , 1990, Fertility and sterility.

[21]  Renyuan Li,et al.  Intracardiac leiomyomatosis: a comprehensive analysis of 194 cases. , 2013, Interactive cardiovascular and thoracic surgery.

[22]  Wolfgang Eiermann,et al.  An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane , 2002, Cancer.

[23]  B. Evans,et al.  Metastasizing Leiomyoma of the Uterus , 1988, The Australian & New Zealand journal of obstetrics & gynaecology.

[24]  T. Glasz,et al.  The diagnosis, morphological particularities, and surgical technique in a case of intravascular leiomyoma extended to the right heart chambers. , 2010, Journal of vascular surgery.

[25]  A. Neri,et al.  Intravascular Leiomyomatosis , 1982, Obstetrics and gynecology.

[26]  L. G. Brito,et al.  Effect of the aromatase inhibitor anastrozole on uterine and leiomyoma Doppler blood flow in patients scheduled for hysterectomy: a pilot study , 2012, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[27]  P. Russell,et al.  Intravenous leiomyomatosis with intracardiac extension - a review of diagnosis and management with an illustrative case. , 2013, Surgical oncology.

[28]  Jian-qun Zhang,et al.  The classification and surgical strategy of intracardiac leiomyomatosis. , 2009, Asian journal of surgery.

[29]  P. Gishen,et al.  Intracardiac spread of intravenous leiomyomatosis with successful surgical excision. , 1980, The New England journal of medicine.

[30]  A. Venkatesan,et al.  Novel hormone treatment of benign metastasizing leiomyoma: an analysis of five cases and literature review. , 2013, Fertility and sterility.

[31]  D. Altınok,et al.  MRI of intravascular leiomyomatosis extending to the heart , 2000, European Radiology.

[32]  A. Mitsuhashi,et al.  GnRH agonist for intravenous leiomyomatosis with cardiac extension. A case report. , 1999, The Journal of reproductive medicine.

[33]  J. V. Nixon,et al.  Intracardiac leiomyomatosis: clinical findings and detailed echocardiographic features--a Chinese institutional experience. , 2014, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[34]  N. Paul,et al.  Intracardiac extension of intravenous leiomyomatosis in a woman with previous hysterectomy and bilateral salpingo-oophorectomy: A case report and review of the literature , 2014 .

[35]  J. Moodley,et al.  Medical management of uterine fibroids with medroxyprogesterone acetate (Depo Provera): a pilot study , 2004, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

[36]  N. Vavatsi-Christaki,et al.  The Effect of Anastrazole on Symptomatic Uterine Leiomyomata , 2007, Obstetrics and Gynecology.

[37]  M Baum,et al.  Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer , 2005, The Lancet.

[38]  C. Karakousis,et al.  Intravenous leiomyomatosis with cardiac extension: tumor thrombectomy through an abdominal approach. , 2000, Journal of vascular surgery.

[39]  A. Kaunitz.  Aromatase inhibitor therapy for uterine bleeding in a postmenopausal woman with leiomyomata. , 2007, Menopause.

[40]  C. Yakut,et al.  Intracardiac extension of intravenous leiomyoma. , 2005, Texas Heart Institute journal.

[41]  R. Nowak.  Fibroids: pathophysiology and current medical treatment. , 1999, Bailliere's best practice & research. Clinical obstetrics & gynaecology.

[42]  I. Manyonda,et al.  Medical management of fibroids. , 2008, Best practice & research. Clinical obstetrics & gynaecology.

[43]  P. Goss,et al.  Aromatase inhibitors in the treatment and prevention of breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  R. Sears,et al.  Metastasizing leiomyoma of the uterus and hormonal manipulations. Case report , 1986, British journal of obstetrics and gynaecology.

[45]  M. Shozu,et al.  In situ estrogen synthesized by aromatase P450 in uterine leiomyoma cells promotes cell growth probably via an autocrine/intracrine mechanism. , 2000, Endocrinology.

[46]  E. Baracat,et al.  Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenopausal patients. , 2009, Fertility and sterility.

[47]  M. Levy,et al.  Tricuspid stenosis due to intravenous leiomyomatosis--a call for caution: case report and review of the literature. , 1982, Texas Heart Institute journal.

[48]  P. Ip,et al.  Uterine Smooth Muscle Tumors Other Than the Ordinary Leiomyomas and Leiomyosarcomas: A Review of Selected Variants With Emphasis on Recent Advances and Unusual Morphology That May Cause Concern for Malignancy , 2010, Advances in anatomic pathology.

[49]  N. Ohara.  Selective estrogen receptor modulator and selective progesterone receptor modulator: therapeutic efficacy in the treatment of uterine leiomyoma. , 2005, Clinical and experimental obstetrics & gynecology.